Showing results (181-190 of 221) with videos related to
Sort By:
Pageof 23
Cell Death and Differentiation|November 5, 2013
Granzyme M targets topoisomerase II alpha to trigger cell cycle arrest and caspase-dependent apoptosisS A H de Poot, K W Lai, L van der Wal, et al.Journal of Clinical Pathology|October 1, 1994
Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinomaP A van Dam, I B Vergote, D G Lowe, et al.Vaccine|August 7, 2016
High frequency ultrasound to assess skin thickness in healthy adultsT J S Van Mulder, M de Koeijer, H Theeten, et al.Epidemiology and Infection|May 8, 2019
The seroprevalence of cytomegalovirus infection in Belgium anno 2002 and 2006: a comparative analysis with hepatitis A virus seroprevalenceG S A Smit, S Abrams, P Dorny, et al.Vaccine|July 12, 2017
Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older AustraliansS Dirmesropian, J G Wood, C R MacIntyre, et al.Vaccine|February 4, 2018
The role of timeliness in the cost-effectiveness of older adult vaccination: A case study of pneumococcal conjugate vaccine in AustraliaC Chen, J G Wood, P Beutels, et al.Acta Clinica Belgica|March 1, 2006
Recommendations for the use of the 23-valent polysaccharide pneumococcal vaccine in adults: a Belgian consensus reportW E Peetermans, N Van de Vyver, Y Van Laethem, et al.Vaccine|November 27, 2019
Skin thickness measurements for optimal intradermal injections in childrenT J S Van Mulder, D Van Nuffel, M Demolder, et al.European Journal of Epidemiology|April 1, 1997
Prevalence of hepatitis A, B and C in the Flemish populationM Beutels, P Van Damme, W Aelvoet, et al.Lancet (London, England)|October 3, 2003
Hepatitis A booster vaccination: is there a need?P Van Damme, J Banatvala, O Fay, et al.Pageof 23